Leptin Receptor Action and Mechanisms of Leptin Resistance

Overview

Journal Cell Mol Life Sci

Publisher Springer

Specialty Biology

Date 2005 Mar 17

PMID 15770417

Citations 75

Authors

H Munzberg

M Bjornholm

S H Bates

M G Myers Jr

Affiliations

Soon will be listed here.

Abstract

The adipose tissue-derived hormone leptin regulates energy balance and neuroendocrine function. Resistance to the appetite-suppressing effects of leptin is associated with common forms of obesity. Here, we review the mechanisms by which leptin activates intracellular signals and the roles that these signals play in leptin action in vivo. Furthermore, we discuss potential mechanisms of leptin resistance, specifically focusing on data regarding the neuroanatomical locus of leptin resistance and potential mechanisms by which expression of the suppressor of cytokine signaling-3 may impair leptin action.

Citing Articles

The role of leptin in the male reproductive system.

Obaideen M, Onel T, Yildirim E, Yaba A J Turk Ger Gynecol Assoc. 2024; 25(4):247-258.

PMID: 39658934 PMC: 11632632. DOI: 10.4274/jtgga.galenos.2024.2023-7-3.

Chronic central nervous system leptin administration attenuates kidney dysfunction and injury in a model of ischemia/reperfusion-induced acute kidney injury.

do Carmo J, Hall J, Furukawa L, Woronik V, Dai X, Ladnier E Am J Physiol Renal Physiol. 2024; 327(6):F957-F966.

PMID: 39361725 PMC: 11687842. DOI: 10.1152/ajprenal.00158.2024.

The Mechanism of Leptin Resistance in Obesity and Therapeutic Perspective.

Engin A Adv Exp Med Biol. 2024; 1460:463-487.

PMID: 39287862 DOI: 10.1007/978-3-031-63657-8_16.

Protein tyrosine phosphatase 1B in metabolic and cardiovascular diseases: from mechanisms to therapeutics.

Sun Y, Dinenno F, Tang P, Kontaridis M Front Cardiovasc Med. 2024; 11:1445739.

PMID: 39238503 PMC: 11374623. DOI: 10.3389/fcvm.2024.1445739.

Targeting Adipokines: A Promising Therapeutic Strategy for Epilepsy.

Shaikh I, Bhatt L Neurochem Res. 2024; 49(11):2973-2987.

PMID: 39060767 DOI: 10.1007/s11064-024-04219-4.

References

Spencer F, Lopes L, Kennedy S, Guyatt G . Systematic review of percutaneous closure versus medical therapy in patients with cryptogenic stroke and patent foramen ovale. BMJ Open. 2014; 4(3):e004282. PMC: 3948581. DOI: 10.1136/bmjopen-2013-004282. View

Capodanno D, Milazzo G, Vitale L, Stefano D, Di Salvo M, Grasso C . Updating the evidence on patent foramen ovale closure versus medical therapy in patients with cryptogenic stroke: a systematic review and comprehensive meta-analysis of 2,303 patients from three randomised trials and 2,231 patients from 11.... EuroIntervention. 2013; 9(11):1342-9. DOI: 10.4244/EIJV9I11A225. View

Carroll J, Saver J, Thaler D, Smalling R, Berry S, MacDonald L . Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med. 2013; 368(12):1092-100. DOI: 10.1056/NEJMoa1301440. View

Udell J, Opotowsky A, Khairy P, Silversides C, Gladstone D, OGara P . Patent foramen ovale closure vs medical therapy for stroke prevention: meta-analysis of randomized trials and review of heterogeneity in meta-analyses. Can J Cardiol. 2014; 30(10):1216-24. DOI: 10.1016/j.cjca.2014.05.004. View

Taaffe M, Fischer E, Baranowski A, Majunke N, Heinisch C, Leetz M . Comparison of three patent foramen ovale closure devices in a randomized trial (Amplatzer versus CardioSEAL-STARflex versus Helex occluder). Am J Cardiol. 2008; 101(9):1353-8. DOI: 10.1016/j.amjcard.2007.12.040. View

Furlan A, Reisman M, Massaro J, Mauri L, Adams H, Albers G . Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med. 2012; 366(11):991-9. DOI: 10.1056/NEJMoa1009639. View

Schwerzmann M, Windecker S, Wahl A, Mehta H, Nedeltchev K, Mattle H . Percutaneous closure of patent foramen ovale: impact of device design on safety and efficacy. Heart. 2004; 90(2):186-90. PMC: 1768045. DOI: 10.1136/hrt.2002.003111. View

Kwong J, Lam Y, Yu C . Percutaneous closure of patent foramen ovale for cryptogenic stroke: a meta-analysis of randomized controlled trials. Int J Cardiol. 2013; 168(4):4132-8. DOI: 10.1016/j.ijcard.2013.07.077. View

Rengifo-Moreno P, Palacios I, Junpaparp P, Witzke C, Morris D, Romero-Corral A . Patent foramen ovale transcatheter closure vs. medical therapy on recurrent vascular events: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J. 2013; 34(43):3342-52. DOI: 10.1093/eurheartj/eht285. View

10.

Wolfrum M, Froehlich G, Knapp G, Casaubon L, DiNicolantonio J, Lansky A . Stroke prevention by percutaneous closure of patent foramen ovale: a systematic review and meta-analysis. Heart. 2013; 100(5):389-95. DOI: 10.1136/heartjnl-2013-304394. View

11.

Tobis J . Patent foramen ovale and the risk of cryptogenic stroke. Cleve Clin J Med. 2014; 81(7):425-6. DOI: 10.3949/ccjm.81a.14066. View

12.

Hausmann D, Mugge A, Becht I, Daniel W . Diagnosis of patent foramen ovale by transesophageal echocardiography and association with cerebral and peripheral embolic events. Am J Cardiol. 1992; 70(6):668-72. DOI: 10.1016/0002-9149(92)90210-p. View

13.

Nagaraja V, Raval J, Eslick G, Burgess D, Denniss A . Is transcatheter closure better than medical therapy for cryptogenic stroke with patent foramen ovale? A meta-analysis of randomised trials. Heart Lung Circ. 2013; 22(11):903-9. DOI: 10.1016/j.hlc.2013.07.022. View

14.

Kistler J, Furie K . Patent foramen ovale diameter and embolic stroke: a part of the puzzle?. Am J Med. 2000; 109(6):506-7. DOI: 10.1016/s0002-9343(00)00599-4. View

15.

Riaz I, Dhoble A, Mizyed A, Hsu C, Husnain M, Lee J . Transcatheter patent foramen ovale closure versus medical therapy for cryptogenic stroke: a meta-analysis of randomized clinical trials. BMC Cardiovasc Disord. 2013; 13:116. PMC: 3890573. DOI: 10.1186/1471-2261-13-116. View

16.

Homma S, Sacco R . Patent foramen ovale and stroke. Circulation. 2005; 112(7):1063-72. DOI: 10.1161/CIRCULATIONAHA.104.524371. View

17.

Maisel W, Laskey W . Patent foramen ovale closure devices: moving beyond equipoise. JAMA. 2005; 294(3):366-9. DOI: 10.1001/jama.294.3.366. View

18.

Pandit A, Aryal M, Aryal Pandit A, Jalota L, Kantharajpur S, Hakim F . Amplatzer PFO occluder device may prevent recurrent stroke in patients with patent foramen ovale and cryptogenic stroke: a meta-analysis of randomised trials. Heart Lung Circ. 2014; 23(4):303-8. DOI: 10.1016/j.hlc.2013.12.003. View

19.

Hagen P, Scholz D, Edwards W . Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc. 1984; 59(1):17-20. DOI: 10.1016/s0025-6196(12)60336-x. View

20.

Dalen J . Are patients with a patent foramen ovale at increased risk of stroke? A billion dollar question. Am J Med. 2007; 120(6):472-4. DOI: 10.1016/j.amjmed.2006.03.021. View